|
21 Companies |
|
21 Products |
|
21 Products |
|
143 Mechanisms of Action |
|
1 Trial |
|
106 News |
|
| 123» |
- | NN1213 / Novo Nordisk
Trial completion: Photobiomodulation Therapy Using the Realief Therapy System for the Treatment of Chemotherapy-associated Peripheral Neuropathy (clinicaltrials.gov) - Feb 11, 2019
P=N/A, N=70, Completed, Sponsor: University of Minnesota - Clinical and Translational Science Institute
Active, not recruiting --> Completed
- | Enrollment change, Trial termination: HOPE: Heading Off Peripheral Neuropathy With Exercise (clinicaltrials.gov) - Nov 1, 2018
P=N/A, N=19, Terminated, Sponsor: University of Nebraska
N=200 --> 19 | Not yet recruiting --> Terminated; Could not recruit total numbers needed. PI left institution.
- | diepalrestat choline (BNV-222) / NeuroMax, BioNevia
Trial completion, Trial primary completion date: 12-Month Efficacy and Safety of Diepalrestat in Adults With Diabetic Peripheral Neuropathy, a DB, Placebo-Controlled Study (clinicaltrials.gov) - Sep 27, 2018
P2/3, N=330, Completed, Sponsor: NeuromaxBionevia
PI left institution. Recruiting --> Completed | Trial primary completion date: Mar 2017 --> Nov 2017
- | Trial completion, Phase classification, Enrollment change, Trial completion date, Trial primary completion date: Dietetic and Hygiene Measures in Metabolic Neuropathies: the Neurodiet Study (clinicaltrials.gov) - Aug 29, 2018
P3, N=8, Completed, Sponsor: Henri Mondor University Hospital
Recruiting --> Completed | Trial primary completion date: Mar 2017 --> Nov 2017 Recruiting --> Completed | Phase classification: PN/A --> P3 | N=40 --> 8 | Trial completion date: Nov 2016 --> Jun 2018 | Trial primary completion date: Nov 2016 --> Jun 2018
- | ASP8477 / Astellas
Phase classification: A Study Into Pain Relief Given by ASP8477 for Peripheral Neuropathic Pain (Either Post-herpetic Neuralgia or Painful Diabetic Peripheral Neuropathy) and Its Safety (clinicaltrials.gov) - Nov 8, 2017
P2a, N=132, Completed, Sponsor: Astellas Pharma Europe B.V.
Recruiting --> Completed | Phase classification: PN/A --> P3 | N=40 --> 8 | Trial completion date: Nov 2016 --> Jun 2018 | Trial primary completion date: Nov 2016 --> Jun 2018 Phase classification: P2 --> P2a
- | Enrollment closed, Trial primary completion date, HEOR: DPN-QoL: Effect of Physical Therapy in Improving the Health of Patients With Diabetic Peripheral Neuropathy (clinicaltrials.gov) - Sep 27, 2017
P=N/A, N=260, Active, not recruiting, Sponsor: National University Health System, Singapore
Phase classification: P2 --> P2a Enrolling by invitation --> Active, not recruiting | Trial primary completion date: Oct 2017 --> Apr 2018
- | paclitaxel / Generic mfg.
Trial completion, Enrollment change, Trial primary completion date: Randomized Placebo-Controlled Trial of Glutamine for Breast Cancer Patients With Peripheral Neuropathy (clinicaltrials.gov) - Aug 18, 2017
P3, N=30, Completed, Sponsor: Weill Medical College of Cornell University
Enrolling by invitation --> Active, not recruiting | Trial primary completion date: Oct 2017 --> Apr 2018 Active, not recruiting --> Completed | N=45 --> 30 | Trial primary completion date: Dec 2017 --> May 2014
- | Enrollment change: Effects of Meditation on Multiple Sclerosis and Peripheral Neuropathy (clinicaltrials.gov) - Mar 3, 2017
P=N/A, N=40, Completed, Sponsor: The Cleveland Clinic
Active, not recruiting --> Completed | N=45 --> 30 | Trial primary completion date: Dec 2017 --> May 2014 N=50 --> 40
- Trial completion, Enrollment change: The Effect of Mindfulness Based Stress Reduction in Patients With Painful Diabetic Peripheral Neuropathy (clinicaltrials.gov) - Sep 15, 2016
P=N/A, N=81, Completed, Sponsor: Ottawa Hospital Research Institute
N=50 --> 40 Active, not recruiting --> Completed | N=110 --> 81
- Trial completion, Enrollment change, Trial primary completion date: Prevalence of Peripheral Neuropathy in Children and Adolescents With Type I Diabetes Mellitus: a Prospective Study (clinicaltrials.gov) - Sep 7, 2016
P=N/A, N=35, Completed, Sponsor: Landeskrankenhaus Feldkirch
Active, not recruiting --> Completed | N=110 --> 81 Recruiting --> Completed | N=80 --> 35 | Trial primary completion date: Dec 2016 --> Dec 2015
- Trial completion: Balancing Treatment Outcomes and Medication Burden Among Patients With Symptomatic Diabetic Peripheral Neuropathy (clinicaltrials.gov) - Sep 7, 2016
P=N/A, N=1270, Completed, Sponsor: Kaiser Permanente
Recruiting --> Completed | N=80 --> 35 | Trial primary completion date: Dec 2016 --> Dec 2015 Enrolling by invitation --> Completed
- ethosuximide / Generic mfg.
Trial completion, Enrollment change, Trial primary completion date: CINE-E: Chemotherapy Induced Painful Peripheral Neuropathy Ethosuximide (The CIN-E Study) (clinicaltrials.gov) - May 26, 2016
P2, N=15, Completed, Sponsor: Royal Marsden NHS Foundation Trust
Enrolling by invitation --> Completed Recruiting --> Completed | N=44 --> 15 | Trial primary completion date: Dec 2012 --> Jul 2014
- Enrollment closed, Trial primary completion date: The Effect of Mindfulness Based Stress Reduction in Patients With Painful Diabetic Peripheral Neuropathy (clinicaltrials.gov) - May 4, 2016
P=N/A, N=110, Active, not recruiting, Sponsor: Ottawa Hospital Research Institute
Recruiting --> Completed | N=44 --> 15 | Trial primary completion date: Dec 2012 --> Jul 2014 Recruiting --> Active, not recruiting | Trial primary completion date: Jan 2016 --> Jun 2016
- bortezomib / Generic mfg.
Trial primary completion date: Chemotherapy-Induced Peripheral Neuropathy Survey (clinicaltrials.gov) - May 3, 2016
P=N/A, N=0, Withdrawn, Sponsor: M.D. Anderson Cancer Center
Recruiting --> Active, not recruiting | Trial primary completion date: Jan 2016 --> Jun 2016 Trial primary completion date: Jan 2014 --> Feb 2013
- Trial primary completion date, HEOR: DPN-QoL: Effect of Physical Therapy in Improving the Health of Patients With Diabetic Peripheral Neuropathy (clinicaltrials.gov) - Mar 25, 2016
P=N/A, N=260, Enrolling by invitation, Sponsor: National University Health System, Singapore
Trial primary completion date: Jan 2014 --> Feb 2013 Trial primary completion date: May 2016 --> Oct 2017
- ||| bortezomib / Generic mfg., thalidomide / Generic mfg.
Trial completion, Trial primary completion date: Serum Vitamin D Levels and Peripheral Neuropathy Among Multiple Myeloma Patients (clinicaltrials.gov) - Mar 10, 2016
P=N/A, N=110, Completed, Sponsor: Oncotherapeutics
Trial primary completion date: May 2016 --> Oct 2017 Recruiting --> Completed | Trial primary completion date: Apr 2016 --> Aug 2015
- Enrollment change, Trial withdrawal: SINF: Peripheral Neuropathy in Cancer Survivors (clinicaltrials.gov) - Mar 8, 2016
P1/2, N=0, Withdrawn, Sponsor: M.D. Anderson Cancer Center
Recruiting --> Completed | Trial primary completion date: Apr 2016 --> Aug 2015 N=120 --> 0 | Not yet recruiting --> Withdrawn
- Enrollment open, Trial primary completion date: Dietetic and Hygiene Measures in Metabolic Neuropathies: the Neurodiet Study (clinicaltrials.gov) - Feb 21, 2016
P=N/A, N=40, Recruiting, Sponsor: Henri Mondor University Hospital
N=120 --> 0 | Not yet recruiting --> Withdrawn Not yet recruiting --> Recruiting | Trial primary completion date: Dec 2012 --> Nov 2016
- Enrollment closed, Trial initiation date, Trial primary completion date: Photobiomodulation Therapy Using the Realief Therapy System for the Treatment of Chemotherapy-associated Peripheral Neuropathy (clinicaltrials.gov) - Feb 21, 2016
P=N/A, N=70, Active, not recruiting, Sponsor: Masonic Cancer Center, University of Minnesota
Not yet recruiting --> Recruiting | Trial primary completion date: Dec 2012 --> Nov 2016 Not yet recruiting --> Active, not recruiting | Initiation date: Jul 2015 --> Jan 2014 | Trial primary completion date: Mar 2016 --> Jul 2015
- paclitaxel / Generic mfg.
Enrollment closed, Trial primary completion date: Randomized Placebo-Controlled Trial of Glutamine for Breast Cancer Patients With Peripheral Neuropathy (clinicaltrials.gov) - Dec 15, 2015
P3, N=45, Active, not recruiting, Sponsor: Linda Vahdat
Not yet recruiting --> Active, not recruiting | Initiation date: Jul 2015 --> Jan 2014 | Trial primary completion date: Mar 2016 --> Jul 2015 Recruiting --> Active, not recruiting | Trial primary completion date: Dec 2010 --> Dec 2017
- Trial completion, Trial primary completion date: In Vivo Corneal Confocal Microscopy for Non-invasive Assessment of Diabetic Peripheral Neuropathy (clinicaltrials.gov) - Dec 6, 2015
P=N/A, N=37, Completed, Sponsor: University of Michigan
Recruiting --> Active, not recruiting | Trial primary completion date: Dec 2010 --> Dec 2017 Recruiting --> Completed | Trial primary completion date: Dec 2016 --> Dec 2015
- |||| diepalrestat choline (BNV-222) / NeuroMax, BioNevia
Trial primary completion date: 12-Month Efficacy and Safety of Diepalrestat in Adults With Diabetic Peripheral Neuropathy, a DB, Placebo-Controlled Study (clinicaltrials.gov) - Dec 5, 2015
P2/3, N=330, Recruiting, Sponsor: NeuromaxBionevia
Recruiting --> Completed | Trial primary completion date: Dec 2016 --> Dec 2015 Trial primary completion date: Jul 2016 --> Mar 2017
- bortezomib / Generic mfg., thalidomide / Generic mfg.
Enrollment change, Trial termination: Acupuncture for Peripheral Neuropathy (clinicaltrials.gov) - Nov 22, 2015
P2, N=8, Terminated, Sponsor: Singapore General Hospital
Trial primary completion date: Jul 2016 --> Mar 2017 N=40 --> 8 | Recruiting --> Terminated; poor recruitment and expiry of funding
- Trial initiation date, Trial primary completion date: SINF: Peripheral Neuropathy in Cancer Survivors (clinicaltrials.gov) - Nov 14, 2015
P1/2, N=120, Not yet recruiting, Sponsor: M.D. Anderson Cancer Center
N=40 --> 8 | Recruiting --> Terminated; poor recruitment and expiry of funding Initiation date: Oct 2015 --> Mar 2016 | Trial primary completion date: Oct 2019 --> Mar 2020
- Enrollment change: Balancing Treatment Outcomes and Medication Burden Among Patients With Symptomatic Diabetic Peripheral Neuropathy (clinicaltrials.gov) - Aug 11, 2015
P=N/A, N=1190, Enrolling by invitation, Sponsor: Kaiser Permanente
Initiation date: Oct 2015 --> Mar 2016 | Trial primary completion date: Oct 2019 --> Mar 2020 N=2124 --> 1190
- | duloxetine / Generic mfg.
Trial completion, Trial primary completion date: Duloxetine in Treating Peripheral Neuropathy Caused by Chemotherapy in Patients With Cancer (clinicaltrials.gov) - Jul 9, 2015
P3, N=242, Completed, Sponsor: Alliance for Clinical Trials in Oncology
N=2124 --> 1190 Active, not recruiting --> Completed | Trial primary completion date: Jan 2010 --> Jan 2012
- | Amiket (amitriptyline/ketamine) / Immune Pharma
Trial completion, Trial primary completion date: ATTRACT-CPN: Topical Amitriptyline and Ketamine Cream in Treating Peripheral Neuropathy Caused by Chemotherapy in Cancer Patients (clinicaltrials.gov) - Jun 10, 2015
P3, N=462, Completed, Sponsor: Gary Morrow
Active, not recruiting --> Completed | Trial primary completion date: Jan 2010 --> Jan 2012 Active, not recruiting --> Completed | Trial primary completion date: Aug 2014 --> Sep 2013
- Enrollment change: Oral Thiamine for the Treatment of Painful Diabetic Peripheral Neuropathy (clinicaltrials.gov) - May 13, 2015
P=N/A, N=0, Withdrawn, Sponsor: Loma Linda University
Active, not recruiting --> Completed | Trial primary completion date: Aug 2014 --> Sep 2013 N=28 --> 0
- Trial completion, Trial primary completion date: Heavy Metal Exposure in Predicting Peripheral Neuropathy in Patients With Stage I-III Breast Cancer Undergoing Chemotherapy (clinicaltrials.gov) - May 4, 2015
P=N/A, N=115, Completed, Sponsor: Fox Chase Cancer Center
N=28 --> 0 Recruiting --> Completed | Trial primary completion date: Dec 2014 --> Apr 2015
- ASP8477 / Astellas
Trial completion: A Study Into Pain Relief Given by ASP8477 for Peripheral Neuropathic Pain (Either Post-herpetic Neuralgia or Painful Diabetic Peripheral Neuropathy) and Its Safety (clinicaltrials.gov) - Apr 29, 2015
P2, N=132, Completed, Sponsor: Astellas Pharma Europe B.V.
Recruiting --> Completed | Trial primary completion date: Dec 2014 --> Apr 2015 Active, not recruiting --> Completed
- Trial initiation date: Photobiomodulation Therapy Using the Realief Therapy System for the Treatment of Chemotherapy-associated Peripheral Neuropathy (clinicaltrials.gov) - Apr 25, 2015
P=N/A, N=70, Not yet recruiting, Sponsor: Masonic Cancer Center, University of Minnesota
Active, not recruiting --> Completed Initiation date: Aug 2014 --> Jul 2015
- Disalcid (salsalate) / Bausch Health
Trial completion, Enrollment change: Pilot Study to Determine Effects of Salsalate in Type 1 Diabetes and Painful Peripheral Neuropathy (clinicaltrials.gov) - Apr 25, 2015
P2, N=8, Completed, Sponsor: University of Michigan
Initiation date: Aug 2014 --> Jul 2015 Active, not recruiting --> Completed | N=10 --> 8
- Trial primary completion date: The Effect of Mindfulness Based Stress Reduction in Patients With Painful Diabetic Peripheral Neuropathy (clinicaltrials.gov) - Apr 22, 2015
P=N/A, N=110, Recruiting, Sponsor: Ottawa Hospital Research Institute
Active, not recruiting --> Completed | N=10 --> 8 Trial primary completion date: Mar 2015 --> Jan 2016
- || bortezomib / Generic mfg., thalidomide / Generic mfg.
Trial primary completion date: Serum Vitamin D Levels and Peripheral Neuropathy Among Multiple Myeloma Patients (clinicaltrials.gov) - Apr 14, 2015
P=N/A, N=110, Recruiting, Sponsor: Oncotherapeutics
Trial primary completion date: Mar 2015 --> Jan 2016 Trial primary completion date: Sep 2014 --> Apr 2016
- Enrollment change: Effect of Exercise on Gait and Balance in Peripheral Neuropathy (clinicaltrials.gov) - Apr 8, 2015
P=N/A, N=101, Completed, Sponsor: Department of Veterans Affairs
Trial primary completion date: Sep 2014 --> Apr 2016 N=165 --> 101
- Enrollment change: Neuragen for Peripheral Diabetic Neuropathy (clinicaltrials.gov) - Mar 17, 2015
P3, N=0, Withdrawn, Sponsor: The Canadian College of Naturopathic Medicine
N=165 --> 101 N=120 --> 0
- Enrollment status: Balancing Treatment Outcomes and Medication Burden Among Patients With Symptomatic Diabetic Peripheral Neuropathy (clinicaltrials.gov) - Mar 17, 2015
P=N/A, N=2124, Enrolling by invitation, Sponsor: Kaiser Permanente
N=120 --> 0 Recruiting --> Enrolling by invitation
- ASP8477 / Astellas
Enrollment closed: A Study Into Pain Relief Given by ASP8477 for Peripheral Neuropathic Pain (Either Post-herpetic Neuralgia or Painful Diabetic Peripheral Neuropathy) and Its Safety (clinicaltrials.gov) - Jan 22, 2015
P2, N=133, Active, not recruiting, Sponsor: Astellas Pharma Europe B.V.
Recruiting --> Enrolling by invitation Recruiting --> Active, not recruiting
- || diepalrestat choline (BNV-222) / NeuroMax, BioNevia
New P2/3 trial: 12-Month Efficacy and Safety of Diepalrestat in Adults With Diabetic Peripheral Neuropathy, a DB, Placebo-Controlled Study (clinicaltrials.gov) - Jan 6, 2015
P2/3, N=330, Recruiting, Sponsor: NeuromaxBionevia
- Trial primary completion date: In Vivo Corneal Confocal Microscopy for Non-invasive Assessment of Diabetic Peripheral Neuropathy (clinicaltrials.gov) - Dec 9, 2014
P=N/A, N=45, Recruiting, Sponsor: University of Michigan
Recruiting --> Active, not recruiting Trial primary completion date: Dec 2013 --> Dec 2016
- Clinical: Ultrasonographic Evaluation of Diabetic Neuropathy (clinicaltrials.gov) - Dec 6, 2014
P=N/A, N=106, Completed, Sponsor: Cukurova University
- Enrollment open, Trial initiation date: Balancing Treatment Outcomes and Medication Burden Among Patients With Symptomatic Diabetic Peripheral Neuropathy (clinicaltrials.gov) - Nov 19, 2014
P=N/A, N=2124, Recruiting, Sponsor: Kaiser Permanente
Trial primary completion date: Dec 2013 --> Dec 2016 Not yet recruiting --> Recruiting | Initiation date: Aug 2014 --> May 2014
- |||| CNV2197944 / Biogen
Trial completion, Enrollment change: Efficacy and Safety of CNV2197944 Versus Placebo in Patients With Diabetic Peripheral Neuropathy (clinicaltrials.gov) - Oct 30, 2014
P2, N=126, Completed, Sponsor: Convergence Pharmaceuticals
Not yet recruiting --> Recruiting | Initiation date: Aug 2014 --> May 2014 Recruiting --> Completed | N=165 --> 126
- |||| ISC 17536 / Glenmark
Trial completion: A Clinical Trial to Study the Effects GRC 17536 in Patients With Painful Diabetic Peripheral Neuropathy (Painful Extremities Due to Peripheral Nerve Damage in Diabetic Patients). (clinicaltrials.gov) - Oct 2, 2014
P2, N=138, Completed, Sponsor: Glenmark Pharmaceuticals Ltd. India
Recruiting --> Completed | N=165 --> 126 Active, not recruiting --> Completed
- paclitaxel / Generic mfg.
Trial completion, Enrollment change: Alpha-lipoic Acid in Patients at Risk for Paclitaxel Induced Neuropathy (clinicaltrials.gov) - Oct 2, 2014
P1/2, N=9, Completed, Sponsor: Northwestern University
Active, not recruiting --> Completed Recruiting --> Completed | N=30 --> 9
- Enrollment open, HEOR: DPN-QoL: Effect of Physical Therapy in Improving the Health of Patients With Diabetic Peripheral Neuropathy (clinicaltrials.gov) - Aug 15, 2014
P=N/A, N=260, Enrolling by invitation, Sponsor: National University Health System, Singapore
Recruiting --> Completed | N=30 --> 9 Not yet recruiting --> Enrolling by invitation
- Trial initiation date: Balancing Treatment Outcomes and Medication Burden Among Patients With Symptomatic Diabetic Peripheral Neuropathy (clinicaltrials.gov) - Aug 7, 2014
P=N/A, N=2124, Not yet recruiting, Sponsor: Kaiser Permanente
Not yet recruiting --> Enrolling by invitation Initiation date: May 2014 --> Aug 2014
- || bortezomib / Generic mfg., thalidomide / Generic mfg.
Trial primary completion date: Serum Vitamin D Levels and Peripheral Neuropathy Among Multiple Myeloma Patients (clinicaltrials.gov) - Jul 12, 2014
P=N/A, N=110, Recruiting, Sponsor: Oncotherapeutics
Initiation date: May 2014 --> Aug 2014 Trial primary completion date: Mar 2014 --> Sep 2014
- Trial initiation date: Photobiomodulation Therapy Using the Realief Therapy System for the Treatment of Chemotherapy-associated Peripheral Neuropathy (clinicaltrials.gov) - Jul 10, 2014
P=N/A, N=70, Not yet recruiting, Sponsor: Masonic Cancer Center, University of Minnesota
Trial primary completion date: Mar 2014 --> Sep 2014 Initiation date: Jan 2014 --> Aug 2014
- || ISC 17536 / Glenmark
Trial primary completion date: A Clinical Trial to Study the Effects GRC 17536 in Patients With Painful Diabetic Peripheral Neuropathy (Painful Extremities Due to Peripheral Nerve Damage in Diabetic Patients). (clinicaltrials.gov) - Jul 1, 2014
P2, N=138, Active, not recruiting, Sponsor: Glenmark Pharmaceuticals Ltd. India
Initiation date: Jan 2014 --> Aug 2014 Trial primary completion date: Jan 2014 --> Aug 2014